Aimmune plans to file for FDA approval by the end of 2018 to give patients a way to protect themselves against accidental exposure to peanut protein.…
The setback leaves Lilly and partner Hanmi Pharmaceutical to weigh whether it is worth moving the Bruton's TKI forward in other indications.
The careful optimization of tumor-bearing humanized models leads to highly useful preclinical immuno-oncology platforms for accelerated immunotherapy…
The takeover gives Roche ownership of the cancer software and real-world evidence that turned GV-backed Flatiron into a rising star.
Roivant and Arbutus have a month to decide if they're going to set up a new company for RNA delivery.
A Celgene spinout known as Celularity with some of the biggest names in biotech and Silicon Valley has raised $250 million for its work in cancer.
Vertex Pharma now has a pair of studies backing up its new drug VX-150, suggesting it can provide opioidlike pain relief without the addiction risks.
The biotech is adding 510 patients to the phase 3 aducanumab trials after seeing more “variability” than expected in a sample size re-estimation.
Bristol-Myers is committing $3.6 billion to a deal that gives Nektar most of the profits and freedom to develop the drug in other combinations.
The setback comes 12 months after Merck pulled the plug on a trial in patients with more advanced forms of the disease.
The Bill & Melinda Gates Foundation has teamed up with big pharma Novartis and its experimental drug for certain diarrheal diseases.